IL136425A - הידרט של תיאזולידינדיאון מותמר, תהליך להכנתו ותכשירים פרמצבטיים המכילים אותו - Google Patents

הידרט של תיאזולידינדיאון מותמר, תהליך להכנתו ותכשירים פרמצבטיים המכילים אותו

Info

Publication number
IL136425A
IL136425A IL13642598A IL13642598A IL136425A IL 136425 A IL136425 A IL 136425A IL 13642598 A IL13642598 A IL 13642598A IL 13642598 A IL13642598 A IL 13642598A IL 136425 A IL136425 A IL 136425A
Authority
IL
Israel
Prior art keywords
hydrate
hydrate according
provides
diabetes mellitus
prophylaxis
Prior art date
Application number
IL13642598A
Other languages
English (en)
Other versions
IL136425A0 (en
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to IL16084798A priority Critical patent/IL160847A0/xx
Publication of IL136425A0 publication Critical patent/IL136425A0/xx
Publication of IL136425A publication Critical patent/IL136425A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13642598A 1997-12-16 1998-12-14 הידרט של תיאזולידינדיאון מותמר, תהליך להכנתו ותכשירים פרמצבטיים המכילים אותו IL136425A (he)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical
PCT/EP1998/008153 WO1999031093A1 (en) 1997-12-16 1998-12-14 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use

Publications (2)

Publication Number Publication Date
IL136425A0 IL136425A0 (en) 2001-06-14
IL136425A true IL136425A (he) 2004-08-31

Family

ID=10823691

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13642598A IL136425A (he) 1997-12-16 1998-12-14 הידרט של תיאזולידינדיאון מותמר, תהליך להכנתו ותכשירים פרמצבטיים המכילים אותו
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same

Country Status (37)

Country Link
US (4) US20020133016A1 (he)
EP (1) EP1042321A1 (he)
JP (1) JP2002508371A (he)
KR (1) KR100549141B1 (he)
CN (3) CN1285831A (he)
AP (1) AP1363A (he)
AR (2) AR017211A1 (he)
AU (2) AU2272299A (he)
BG (1) BG64850B1 (he)
BR (1) BR9813598A (he)
CA (1) CA2314967A1 (he)
CO (1) CO4990943A1 (he)
CZ (1) CZ300081B6 (he)
DZ (1) DZ2679A1 (he)
EA (1) EA002833B1 (he)
EG (1) EG22250A (he)
GB (1) GB9726563D0 (he)
HR (1) HRP20000404A2 (he)
HU (1) HUP0102292A3 (he)
ID (1) ID24714A (he)
IL (2) IL136425A (he)
MA (1) MA26581A1 (he)
MY (1) MY128573A (he)
NO (1) NO317255B1 (he)
NZ (1) NZ504703A (he)
OA (1) OA11900A (he)
PE (1) PE20000125A1 (he)
PL (1) PL341213A1 (he)
RS (1) RS50080B (he)
SA (1) SA99200200B1 (he)
SK (1) SK286422B6 (he)
TR (2) TR200001793T2 (he)
TW (1) TW487709B (he)
UA (1) UA66821C2 (he)
UY (2) UY25309A1 (he)
WO (1) WO1999031093A1 (he)
ZA (1) ZA9811504B (he)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
HK1045152A1 (zh) * 1999-04-23 2002-11-15 Smithkline Beecham Plc 噻唑烷二酮衍生物及其用作抗糖尿病藥的應用
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
AU765498B2 (en) * 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
JPH09512249A (ja) * 1994-02-10 1997-12-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 腎臓疾患を治療するためのインスリンセンシタイザーの使用
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
MXPA03002580A (es) 2000-09-26 2003-10-15 Cord Janet I Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.

Also Published As

Publication number Publication date
NZ504703A (en) 2002-12-20
UY25306A1 (es) 2000-12-29
UY25309A1 (es) 1999-07-19
BG64850B1 (bg) 2006-06-30
YU36400A (sh) 2003-12-31
JP2002508371A (ja) 2002-03-19
BR9813598A (pt) 2000-10-10
AP1363A (en) 2005-01-21
AU2753802A (en) 2002-05-16
AU770818B2 (en) 2004-03-04
NO317255B1 (no) 2004-09-27
HRP20000404A2 (en) 2000-12-31
WO1999031093A1 (en) 1999-06-24
GB9726563D0 (en) 1998-02-11
SK9182000A3 (en) 2000-12-11
CN101318956A (zh) 2008-12-10
AP2000001829A0 (en) 2000-06-30
KR100549141B1 (ko) 2006-02-03
SK286422B6 (sk) 2008-09-05
CZ20002206A3 (cs) 2000-12-13
PE20000125A1 (es) 2000-03-03
CN101318957A (zh) 2008-12-10
CA2314967A1 (en) 1999-06-24
US20070037859A1 (en) 2007-02-15
OA11900A (en) 2006-04-10
EA002833B1 (ru) 2002-10-31
CN1285831A (zh) 2001-02-28
AR017211A1 (es) 2001-08-22
TW487709B (en) 2002-05-21
CZ300081B6 (cs) 2009-01-28
BG104606A (en) 2001-02-28
ZA9811504B (en) 2000-06-15
US20050288513A1 (en) 2005-12-29
HUP0102292A2 (hu) 2002-05-29
US20020133016A1 (en) 2002-09-19
SA99200200B1 (ar) 2006-11-11
HUP0102292A3 (en) 2003-12-29
RS50080B (sr) 2009-01-22
TR200001793T2 (tr) 2000-10-23
UA66821C2 (uk) 2004-06-15
US20030139604A1 (en) 2003-07-24
EA200000656A1 (ru) 2000-12-25
AU2272299A (en) 1999-07-05
PL341213A1 (en) 2001-03-26
EP1042321A1 (en) 2000-10-11
IL136425A0 (en) 2001-06-14
TR199802624A3 (tr) 1999-10-21
US7368574B2 (en) 2008-05-06
MA26581A1 (fr) 2004-12-20
EG22250A (en) 2002-11-30
ID24714A (id) 2000-08-03
NO20003070L (no) 2000-06-15
AR016161A1 (es) 2001-06-20
CO4990943A1 (es) 2000-12-26
NO20003070D0 (no) 2000-06-15
TR199802624A2 (xx) 1999-10-21
IL160847A0 (en) 2004-08-31
KR20010033140A (ko) 2001-04-25
DZ2679A1 (fr) 2003-03-29
MY128573A (en) 2007-02-28

Similar Documents

Publication Publication Date Title
AU770818B2 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US20070203200A1 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
EP1173434B1 (en) Thiazolidinedione derivative and its use as antidiabetic
EP1661895A1 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,maleic acid salt,hydrate as pharmaceutical
US7045633B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US6664278B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
AU774613B2 (en) Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
AU770817B2 (en) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
HK1092138A (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
ZA200108722B (en) Thiazolidinedione derivative and its use as antidiabetic.
HK1110326A (en) Novel pharmaceutical